



A High Throughput Technology for Identifying Drugs to Combat Neurodegeneration and Aging



84

million
People older than
65 years

14



million
Alzheimer's and
related dementias

\$1.1

trillion
Expenditure for
neurodegenerative diseases



* Estimated figures by 2050



Technology Features

- No manual manipulation of animals
- Automated scoring of animal health/survival
- Temporal manipulation of animal environment
- Portable, bench-top, and plug & play unit

Applications

- Drug compound screening
- Toxicology testing
- Genetic and RNAi screens
- Mechanistic studies



Siva A. Vanapalli, Ph.D.
President and CEO
NemaLife Inc.

Mizanur Rahman, Ph.D.
Chief Technology Officer
NemaLife Inc.

Taslim Anupom
Research Engineer
NemaLife Inc.

Contact us: Email: nemalifeinc@gmail.com, P. O. Box 6477, Lubbock, Texas-79413

